ChromaDex founder Frank Jaksch resigns as executive director and employee; remains chairman

Niagen Bioscience, Inc.

Frank L. Jaksch, Jr. resigns as executive director and employee effective June 30, 2022.
He will continue to serve on the Board as Chairman of the Board.
Resignation also covers all officer, employee, director roles at subsidiaries.
Company is ChromaDex Corporation (CDXC).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Frank L. Jaksch, Jr.

Executive Director

NAGE · Niagen Bioscience, Inc.

Effective: 2022-06-30
Filed: June 9, 2022, 7:59 PM ET

On June 3, 2022, Frank L. Jaksch, Jr. notified ChromaDex Corporation (the “Company”) of his intention to resign as executive director and employee of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Frank L. Jaksch, Jr. resigned as Executive Director at Niagen Bioscience, Inc..

Action: resigned
Role: Executive Director

Exact text from the filing

On June 3, 2022, Frank L. Jaksch, Jr. notified ChromaDex Corporation (the “Company”) of his intention to resign as executive director and employee of the Company

View on SEC.gov

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-016696

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.